Collaboration and License Agreements - Fulcrum Therapeutics, Inc (Details) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	May 31, 2025 USD ($)	Jul. 31, 2023 USD ($) performanceObligation milestone	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)
Collaboration and License Agreements
Research and collaboration revenue			$ 795	$ 0	$ 3,150	$ 0
Fulcrum Therapeutics, Inc.
Collaboration and License Agreements
Deferred revenue		$ 400
Number of performance obligations | performanceObligation		1
Fixed consideration amount		$ 400
Proceeds from milestone payment	$ 600
Milestone payment included in transaction price	600
Research and collaboration revenue	$ 600
Fulcrum Therapeutics, Inc. | Tier 1 Product | Minimum
Collaboration and License Agreements
Development and commercial one time milestone receivable | milestone		1
Variable consideration amount		$ 600
Fulcrum Therapeutics, Inc. | Tier 1 Product | Maximum
Collaboration and License Agreements
Variable consideration amount		$ 20,000